Trial Profile
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Busulfan; Gemcitabine; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 29 Jun 2023 Planned End Date changed from 30 Aug 2023 to 30 Aug 2024.
- 29 Jun 2023 Planned primary completion date changed from 30 Aug 2023 to 30 Aug 2024.
- 27 Mar 2023 Planned End Date changed from 28 Feb 2023 to 30 Aug 2023.